The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Clinical characterstics and outcomes of patients with BRAF-mutant advanced cancer in a phase I clinic: The University of Texas M. D. Anderson Cancer Center experience.
H. E. El-Osta
No relevant relationships to disclose
G. S. Falchook
Research Funding - GlaxoSmithKline
A. M. Tsimberidou
No relevant relationships to disclose
D. S. Hong
No relevant relationships to disclose
A. Naing
No relevant relationships to disclose
K. B. Kim
No relevant relationships to disclose
S. Wen
No relevant relationships to disclose
F. Janku
No relevant relationships to disclose
R. Kurzrock
Research Funding - AstraZeneca; Bayer; Genentech; GlaxoSmithKline